Drug-induced movement disorders by Zádori, Dénes et al.
EXPERT OPINION ON DRUG SAFETY 14:(6) pp. 877-890. (2015)
Drug-induced movement disorders
Authors: Dénes Zádori1, Gábor Veres1, Levente Szalárdy1, Péter Klivényi1, László Vécsei1,2
Affiliations:
1Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center,
University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary
zadori.d  e  n  e  s@  m   e d.u  - s  ze   g e  d.hu, veresg.g   y t  k @   g m   a il   .c  o  m  , szalardy. l  e v  e  n  t  e  @ m   e d.u-
szeged.hu, klivenyi.p  e  t  er  @ m   e d.u  - s  z   e g  e  d.hu, vecsei. l  a s  z   l o@ m   e d.u  - s  z   e g  e  d  .  hu
2 




László Vécsei MD, PhD, DSc
Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center,
University of Szeged,
Semmelweis u. 6, H-6725 Szeged, Hungary
Phone:+36(62)545351; Fax: +36(62)545597
E-mail: vecsei. l  a s  z   l o@ m   e d.u  - s  z   e g  e  d.hu
Abstract
Drug-induced movement disorders (DIMDs) can be elicited by several kinds of 
pharmaceutical agents. The major groups of offending drugs include antipsychotics, 
antidepressants, calcium channel blockers, antiepileptics, gastrointestinal drugs, mood 
stabilizers, antimicrobials, antiarrhythmics and chemotherapeutic agents among others. 
Although the number of offending agents and reported cases are variable, on the whole, all 
kinds of movement disorders can be evoked by pharmaceuticals. Therefore, when we observe 
a patient with a movement disorder of relatively recent onset, the possibility of DIMDs should
always be considered among other secondary and treatable conditions. As the treatment of 
some DIMDs is quite challenging, a preventive approach is preferable. Accordingly, we
should be very cautious with the prescription of pharmaceuticals that are able to induce severe
adverse effects, i.e. their use should be strictly limited to appropriate indications and they 
should be applied in as low doses as the patient’s condition allows and only for the shortest 
adequate duration. As most of DIMDs are related to an unspecific adverse action of 
medications in the basal ganglia and the cerebellum, future research should focus on better 
characterization of the neurochemical profile of the affected functional systems, in addition to
the development of drugs with higher selectivity and better side-effect profile. Furthermore, 
special attention should be paid to the exploration of genetic and environmental factors 
influencing drug responsiveness, interactions and side-effect profile.
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Article highlights
Most of DIMDs are related to an unspecific adverse action of the offending agents in
the basal ganglia and the cerebellum; therefore, better characterization of the 
neurochemical profile of the affected functional systems is one of the most important
cues for future research.
DIMDs are frequently overlooked by the clinical community, leading to a general 
increase in the incidence of these mostly reversible conditions; therefore, high-quality
education is essential to achieve early recognition.
The most important factor in the management of DIMDs is prevention: i.e. the 
offending agents should be administered for as short duration and in as low doses as
the patient’s condition allows.
In case the withdrawal of the offending drug is insufficient to provide proper 
symptomatic relief, certain pharmaceuticals may play special roles in the 
amelioration of DIMDs.
Tardive syndromes, which can also occur following dose reduction or a sudden
withdrawal of the offending drug, represent the highest therapeutic challenge.
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1. Introduction
Drug-induced  movement disorders (DIMDs) can be caused by several kinds of agents and
almost all sorts of movement disorders can occur as a result of medication side effect (Table
1; [1]). The underlying pathomechanism is only known in a subset of DIMDs; however, an
altered neurotransmission in the basal ganglia (predominantly in the striatum; Fig. 1) and the
cerebellum is presumed to play a role. Based on the onset of symptoms, DIMDs can be
classified as acute (occurring within hours to days), subacute (occurring after days to weeks)
or chronic (occurring after months spent in the exposure of the offending drug). Following the
initial presentation of tardive syndromes, which represent the most challenging  conditions
among DIMDs,  the current review focuses on the concise delineation of each movement
disorder  induced by pharmaceuticals as well as on the discussion of potential therapeutic
options. The description of laboratory chemicals, illicit drugs or recreational substances able
to induce movement disorders is out of the scope of this paper.
2. Drug-induced movement disorders
2.1 On the significance of tardive syndromes
Among chronic DIMDs, tardive dyskinesias (TDs) represent a rather specific subgroup [2,3].
TDs represent a group of neuroleptic-induced delayed-onset iatrogenic movement disorders,
which can manifest in stereotypy,  dystonia, akathisia, tic, tremor, myoclonus,  chorea,
parkinsonism, withdrawal emergent syndrome and neuroleptic malignant syndrome (NMS).
Furthermore, in some cases, sensory symptoms such as paresthesia, pain and an inner urge to
move can also accompany the movement disorders. The term ‘classic TD’ was introduced to
describe the prototypical oro-bucco-lingual  stereotypic movements [2]. In addition to the
exposure  to neuroleptics (a duration-  and dose-related effect [4]), older age [5], African-
American ethnicity [6], the presence of diabetes mellitus [7]  and the occurrence of acute
dystonic reactions or parkinsonism [4] may be the major predisposing  risk factors for the
development of TD. Even third-generation  antipsychotics (e.g. aripiprazole [8]) have the
potency  to evoke TD. The proposed pathomechanisms of TD include dopamine 2 receptor
upregulation with subsequent hypersensitivity, gamma-aminobutyric  acid (GABA)
insufficiency, increased endogenous opioid effect, glutamate excitotoxicity, oxidative stress
and  genetic susceptibility as  well  [2,3].  In  addition to  neuroleptics, antidepressants (e.g.
duloxetine  [9]), mood stabilizers (e.g. lithium [10]) and calcium channel blockers (e.g.
flunarizine [11]) can also induce tardive syndromes. The prevalence of neuroleptic-induced
TD is relatively high, reaching approximately 20% [12]. In addition to the development of TD
while the patients are on medication, the condition can also occur following dose reduction or
a sudden withdrawal of the applied neuroleptic drug  [13]. The special importance of the
distinction of TD from other DIMDs, especially from those with relatively rapid onset, is
based on therapeutic considerations. In most cases of TD, in contrary to acute- or subacute-
onset DIMDs, clinicians face therapeutic challenges. In a considerable number of cases, the
beneficial effect of dose-reduction or switching to a medication with better side-effect profile
is  questionable and the treatment  armory is  limited  as  well. First of all,  the  preventive
approach is preferable: we should be very cautious with the prescription of neuroleptics and
they are ought to be used when they are strictly indicated and only  for as short period as
possible and in as low doses as the condition allows [14]. In general, with regard to the limited
therapeutic options in TD, mostly vesicular monoamine transporter (VMAT) inhibitors (e.g.
tetrabenazine [15]) amantadine [16], benzodiazepines (e.g. clonazepam [16]), anticholinergics
(e.g. trihexyphenidyl  [17]), beta-blockers (e.g. propranolol [18]), antiepileptics (e.g.
levetiracetam [19]), chemodenervation with botulinum toxin injections [20]  or deep brain
stimulation [21,22] may come into account.
2.2 Drug-induced parkinsonism
Probably the most important criterion of drug-induced parkinsonism (DIP) is the absence of 
history of parkinsonism before the administration of the offending drug [23]. Therefore, the 
exclusion of idiopathic Parkinson’s disease (iPD [24]) in the differential diagnostic workup of
DIP (the second most common cause of parkinsonism after iPD [25]) is essential. Fortunately,
there are some valuable tools for this workup [26]. With regard to clinical phenomenology,
the development of symptoms within 3 months, the symmetrical presentation of symptoms, 
the relative absence of resting tremor, the coexistence of oromandibular dyskinesias and poor
or absent response to levodopa all favor the diagnosis of DIP [23,27]. Although the formal 
indication of DaT-SCAN™ (a single photon emission computed tomography using 123I- 
ioflupane as dopamine transporter ligand; GE Healthcare) does not include its applicability in
the differential diagnosis between iPD and DIP [28], some evidence suggest that it still might 
be a reliable technique for that purpose [29,30]. Similarly, other radiopharmacons can also be 
utilized [31].The application of smell test for the evaluation of olfactory function or cardiac 
metaiodobenzylguanidine scintigraphy for the assessment of myocardial sympathetic
innervation may also be helpful, as a significant impairment in olfactory function and the 
uptake of the radiopharmaceutical are typical of iPD but not of DIP [32,33]. With regard to
tardive parkinsonism, although the parkinsonian features persist for years after the 
discontinuation of the offending agent, the DaT-SCAN™ is normal [2].
The most common cause of DIP is related to antipsychotic medications [34]. Although 
atypical antipsychotics have better side-effect profile than typical ones, they can also provoke
DIP when applied in higher doses [35], except clozapine, in case of which the risk of 
developing DIP is the same as in case of placebo [36]. The pathomechanism of DIP due to 
antipsychotics is the blockade of striatal D
2 
dopaminergic receptors in an extent higher than
75-80% [37]. Other dopamine receptor blocking agents (DRBAs), such as benzamide
derivative antiemetics (e.g. metoclopramide [38]), dopamine synthesis blockers (e.g. alpha- 
methyldopa [39]) or VMAT inhibitors (e.g. tetrabenazine [40]) can also induce DIP. Certain 
calcium channel antagonists (e.g. flunarizine or cinnarizine) can accompany the development
of DIP as well, via decreasing neuronal activity and thereby reducing monoaminergic 
neurotransmission [41]. Furthermore, in rare occasions, antiepileptics (e.g. valproate [42]) 
mood stabilizers (e.g. lithium [43]), antiarrhythmics (e.g. amiodarone [44]), antidepressants 
(e.g. some selective serotonin reuptake inhibitors (SSRIs) [45,46]), immunosuppressants (e.g.
cyclosporine [47]), statins (e.g. lovastatin [48]) and antimicrobials (e.g. amphotericin B [49]) 
have also been associated with DIP.
The treatment of DIP is challenging for the clinicians. First of all, the reduction of dose may 
offer some help; however, in most cases the substitution of the offending agent with a 
medication that has better side-effect profile would be necessary [1]. Levodopa, dopamine 
agonists or anticholinergics usually have no effect [23]. In approximately 25% of patients with
suspected DIP, a symptomatic relief cannot be achieved and a differentiation of these cases 
from ‘pure’ DIP is necessary [50]. These complicated cases presenting with persistent or 
progressive parkinsonism may predominantly represent a preclinical stage of iPD or other 
degenerative conditions associated with parkinsonism or a condition developed owing to the 
direct neurotoxic effect of the offending agent to the nigrostriatal dopaminergic neurons [51]. 
Parkinsonism-hyperpyrexia syndrome (PHS) is a rare condition mainly caused by a rapid 
reduction or withdrawal of antiparkinsonian medications [1]. The condition is characterized
by severe akinesia, altered mental state and drowsiness, dysautonomia and fever with 
elevated level of creatine kinase, and may be precipitated by respiratory tract infection, acute 
gastrointestinal problems or traumatic injuries [52]. A slow symptomatic relief can be
achieved in PHS after the restoration of previously applied treatment, in some severe cases,
however, only subcutaneous apomorphine injections or intravenous amantadine infusions may
offer some help, if any.
2.3 Drug-induced tremor
The onset of drug-induced tremor (DIT) is typically temporally related to the initiation of the 
therapy and the applied dose positively correlates with the extent of tremor [53]. However, the
establishment of the diagnosis of DIT should be preceded by the careful exclusion of 
conditions with a progressive disease course (e.g. in cases of parkinsonian, essential, tumor- 
related tremors) and the possible presence of other underlying medical conditions (e.g. 
hyperthyreoidism, hypoglycemia, vascular lesion, multiple sclerosis). Almost all types of 
tremor, i.e. presenting at rest or action (postural, kinetic and intention) can be induced by 
medicines [54]. Furthermore, they can occur in a combination as well. Antiarrhythmics (e.g. 
amiodarone – postural [55]), antimicrobial agents (e.g. trimethoprim-sulfamethoxazole – 
resting [56]), antidepressants (e.g. amitriptyline and SSRIs – postural and resting [57,58]), 
mood stabilizers (e.g. lithium – postural, intention and resting [59]), antiepileptics (e.g. 
valproate – postural and resting [60]), bronchodilators (e.g. salbutamol – postural and
intention [61]), chemotherapeutics (e.g. cytarabine, thalidomide – postural, intention and 
resting, respectively [62,63]), gastrointestinal drugs (e.g. metoclopramide – postural and 
resting [64,65]), hormones (e.g. levothyroxine overdose – postural [66]), immunosuppressants
(e.g. cyclosporine – postural and intention [67]), psychostimulants (e.g. methylphenidate –
postural [68]) neuroleptics and VMAT inhibitors (e.g. haloperidol and tetrabenazine – postural 
and resting [69,70]) can all evoke DIT, sometimes as part of DIP. Therapeutic approaches are 
similar to that described in DIP, i.e. first a reduction of dose or switching to a medication with a 
lower ability to induce tremor is suggested. If necessary, evidence indicates that propranolol 
may improve drug-induced action tremor, whereas anticholinergics and amantadine might
ameliorate drug-induced resting tremor [1,53]. With regard to tardive tremor, VMAT
inhibitors (e.g. tetrabenazine) can be applied in the absence of parkinsonian features [71].
2.4 Drug-induced chorea (± athetosis and ballismus)
Chorea, athetosis and ballismus are usually hardly distinguishable from each other; however, 
some distinctions can be made by the speed and the location of abnormal involuntary 
movements. Therefore, in this review, the discussion is limited to drug-induced chorea (DIC),
keeping in mind that the below listed offending agents can evoke an overlapping spectrum of 
the chorea/athetosis/ballismsus triad. The most common causes of DIC are levodopa and 
antipsychotics [14,72,73]. Levodopa results in the development of levodopa-induced 
dyskinesia (LID) in about 40% of patients with iPD after 4-6 years of use [74]. The most 
important risk factors for the development of LID are proposed to be the duration of disease 
and the dose of levodopa [75]. With regard to the pathomechanism of LID, maladaptive 
corticostriatal synaptoplasticity seems to be one of the most important factors [14,76]. Tardive
chorea is rarely seen as the only side effect of neuroleptics, as it usually accompanies the
classic oro-bucco-lingual TD. However, it can manifest after the discontinuation of DRBAs in
children in the form of withdrawal emergent syndrome [13].
Several kinds of antiepileptics (e.g. phenytoin [77]) have been reported to induce chorea on 
rare occasions. Tricyclic and SSRI antidepressants have both been linked to DIC [78] via the 
reduction of serotonergic attenuation of dopaminergic transmission [79]. With regard to oral 
contraceptives, both estrogen- and progesterone-containing pills can result in the development
of choreiform movements [80]. The underlying proposed pathomechanism is that these 
medications result in an enhanced dopaminergic effect in the basal ganglia [81]. 
Psychostimulants (e.g methylphenidate [82]) are capable of inducing chorea on the one hand 
by enhancing the presynaptic striatal dopamine release, and on the other hand by the
inhibition of dopamine uptake by dopamine transporters [83]. DIC may also develop due to 
anticholinergics (e.g. trihexyphenidyl [84]), probably via the inhibition of central 
acetylcholine receptors. Antihistamines (e.g. cyproheptadine [85]) represent a probably 
uncommon cause of DIC with a currently unknown pathomechanism. Existing hypotheses 
include a competitive inhibition of histamine receptors in the basal ganglia as a possible 
mechanism of action [86]. Rarely, other medications, such as opioids (e.g. methadone [87]), 
antiarrhythmics (e.g. digoxin [88]), mood stabilizers (e.g. lithium [89]), antimetabolites (e.g.
methotrexate [90]) and central muscle relaxants (e.g. baclofen [91]) are also capable of 
inducing DIC.
Acute or subacute DIC mostly disappears after the discontinuation of the offending agent [1].
Being a self-limiting condition, withdrawal emergent syndrome usually does not require any 
treatment either [2]. However, if necessary, the DRBAs can be reinstituted and tapered off 
gradually.
2.5 Drug-induced dystonia
Acute dystonic reactions (ADRs) are mostly observed following an exposure to DRBAs [1], 
i.e. to neuroleptics (predominantly the conventional ones [92,93]), to antiemetics and to 
gastrointestinal promotility agents. However, the occurrence of ADR may also be linked to 
antidepressants (e.g. SSRIs, probably via the overstimulation of serotonine 5-HT
2 
receptors in
the basal ganglia [78,94]), calcium channel blockers (e.g. nifedipine, probably via altering 
central dopamine production through N-type calcium channels [95,96]). On rare occasions, 
opioids (e.g. fentanyl [97]), psychostimulants (e.g. methylphenidate [98]), acetylcholinesterase
inhibitors (e.g. rivastigmine, via the proposed indirect inhibition of striatal D
1 
dopaminergic 
receptors through the overstimulation of muscarinic M
4 
receptors [99,100]), antimicrobials 
(e.g. albendazole [101]), antiepileptics (e.g. carbamazepine [102]), antihistamines (e.g.
cetirizine [103]), benzodiazepines (e.g. midazolam [104]), histamine H
2 
receptor blockers (e.g.
ranitidine [105]), chemotherapeutic agents (e.g. 5-fluorouracil [106]), non-steroid anti- 
inflammatory drugs (NSAID, e.g. ibuprofen [107]) and anesthetics (e.g. propofol [108]) can 
also induce dystonic reactions. Although drug-induced dystonia (DID) predominantly affects 
craniocervical muscles resulting in torticollis, retrocollis or oromandibular dystonia [1,109], it
can manifest in trismus, laryngospasm, pharyngeal dystonia, oculogyric crisis and limb 
dystonia as well [78]. In severe cases of ADR, the cessation of use of the offending agents is 
usually insufficient; however, they dramatically respond to intravenous or intramuscular 
injections of anticholinergic drugs [1]. If adequately repeated doses of anticholinergics are not
effective, benzodiazepines (e.g. diazepam) may also be tried [96]. Furthermore, botulinum 
toxin injections may also serve as a therapeutic option in certain focal dystonias [110]. In 
tardive dystonia, the administration of tetrabenazine or the application of a DRBA with 
minimal potency of worsening TD (e.g. clozapine) may be the first therapeutic choice [111].
In case the appropriate symptom control cannot be achieved by the selected anti- 
dopaminergic medications, anticholinergic medications can also be tried. If pharmaceutical
treatment is ineffective, pallidal deep brain stimulation can be considered.
2.6 Drug-induced ataxia
Depending on the predominantly affected region of the nervous system, ataxia can be 
classified into three subtypes: cerebellar, vestibular and sensory. Drug-induced ataxia (DIA) 
can occur as a result of a temporary or permanent dysfunction of these systems alone or in 
combination. DIA can be caused by benzodiazepines with hypnotic effect (e.g. flunitrazepam
[112]), barbiturates (e.g. phenobarbital [113]), sleeping pills (e.g. zolpidem [114]), central 
muscle relaxants (e.g. baclofen [115]) and antiepileptics (e.g. carbamazepine [116]) via a 
significant reduction of neuronal firing in the cerebellum. However, some antiepileptics (e.g.
phenytoin [117]) can result in cerebellar damage and permanent ataxia. Some of the agents 
that have ototoxic effects might have an accompanying vestibulotoxic effect as well, 
mimicking the development of a cerebellar syndrome [118]. Some antimicrobials (e.g. 
gentamycin [119]) and chemotherapeutics (e.g. vincristine [120]) have proved to exert such 
vestibulotoxic effects. Medication-induced sensory- or mixed neuropathies may both be 
responsible for a sensory ataxia [121]. From this aspect, the major offending agents are 
chemotherapeutics (e.g cisplatin [121]), statins [122], antiarrhythmics (e.g. amiodarone [123]) 
and antimicrobials (e.g. nucleoside analogs [124]). The harm is related to the neurotoxic effect
of these drugs.
From a therapeutic point of view, considering the neurotoxic properties of the offending 
agents, the prevention of the development of DIA would be a major aim, i.e. we should use
these drugs in as low dose and for as short duration as possible.
2.7 Drug-induced myoclonus
When talking about myoclonus, we should distinguish between positive and negative (i.e.
asterixis) ones. The group of the most common offending agents related to drug-induced 
positive myoclonus (DIPM [125]) consists of antibiotics (e.g. quinolones), antidepressants
(e.g. SSRIs), anxiolytics (e.g. benzodiazepines) and opioids (e.g. morphine). Furthermore,
antiparkinsonian agents (e.g. levodopa [126]), DRBAs (e.g. metoclopramide [127]),
acetylcholinesterase inhibitors (e.g. donepezil [128]), antiepileptics (e.g. carbamazepine [129]),
calcium channel blockers (e.g. amlodipine [130]), antiarrhythmics (e.g. amiodarone [131]), 
chemotherapeutics (e.g. 5-fluorouracil [132]) and anesthetics (e.g. etomidate [133]) can evoke 
DIPM, as well. Tardive positive myoclonus typically occurs in the upper extremities [134]. 
DIPM usually ceases after the discontinuation of the offending agent.
In case of a drug-induced asterixis, antiepileptics represent the most common cause when 
their serum levels reach a toxic range [78]. Therefore, the proper therapeutic approach is dose
reduction.
2.8 Drug-induced tic
Tic, which is a rapid stereotyped movement and/or vocalization, can be provoked by several
pharmaceutical agents [78]. These drugs include psychostimulants (e.g. methylphenidate 
[135]), antidepressants (e.g. amisulpride [136]) and antiepileptics (e.g. carbamazepine [137]).
Of note, the latter one does not resolve after the discontinuation of the offending agent, but 
improves with the application of haloperidol.
2.9 Other specific drug-induced conditions
Akathisia, which can be described as an intense inner urge to move, i.e. the strong feeling of 
restlessness [1], can occur as an acute or chronic DIMD, and sometimes in the form of a 
tardive syndrome [2]. The offending agents are DRBAs. Acute akathisia can be stopped by 
dose reduction or the discontinuation of the drug that evoked it. However, when these actions
cannot be implemented, anticholinergics, beta-blockers, benzodiazepines, amantadine, 
mirtazapine or clonidine can yield some relief [1].
Although classic TD represent the most common form of tardive strereotypy, stereotypic 
movements can occur in the limbs as well, as a result of neuroleptic side-effect [2]. 
Neuroleptic malignant syndrome is an idiosyncratic reaction to DRBAs (on dose escalation or
a sudden withdrawal of stable doses) with potentially severe consequences [1]. The typical 
symptoms of NMS include fever, autonomic instability, altered mental state and certain 
movement disorders (rigidity, tremor, dystonia and myoclonus). The characteristic laboratory 
findings include elevated serum creatine kinase, elevated liver enzymes, leukocytosis,
electrolyte disturbance, altered renal functions and coagulation. These may be accompanied 
by ECG abnormalities. To improve the diagnostic workup, the Delphi consensus method has 
been established [138]. The therapeutic approaches comprise an immediate discontinuation of
the offending agent, the introduction of dopaminergic agonists and supportive care if 
necessary. Dantrolene and benzodiazepines may also provide beneficial effects with regard to
rigidity and rhabdomyolysis. The duration of treatment should be long enough to prevent a 
relapse.
Serotonin syndrome (SS) represent another acute drug-induced condition resembling NMS 
[1]. The offending agents are those that increase serotonergic activity, e.g. SSRIs, serotonin-
norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors,
lithium, opioids and antiepileptics [139]. The characteristic symptoms include agitation, 
anxiety, confusion or euphoria, dysautonomia with fever, tachycardia, elevated blood 
pressure, tachypnea, diaphoresis and diarrhea and certain movement disorders (tremor, 
akathisia, myoclonus and rigidity). From therapeutic aspect, in case the immediate 
discontinuation of the culprit medication is not enough to achieve symptomatic relief, 
benzodiazepines (e.g. diazepam) or serotonin 5-HT
2A 
receptor antagonist (e.g. 
cyproheptadine) can be applied in severe cases.
Restless legs syndrome (RLS), periodic limb movements of sleep (PLMS) and rapid eye 
movement (REM) sleep behavior disorder/REM sleep without atonia (RBD/RSWA) can all 
manifest as medication-induced movement disorders as well [140]. Antidepressants (e.g. 
SSRIs [141]), mood stabilizers (e.g. lithium [142]), levodopa/carbidopa [143], hormones (e.g.
L-thyroxine [144]), antipsychotics (e.g. olanzapine [145]), antiepileptics (e.g. phenytoin [146]),
histamine H
2 
receptor blockers (e.g. cimetidine [147]) and opioids (e.g. tramadol [148]) can all
evoke RLS, which can be characterized by a strong urge to move the lower limbs at rest or an
inactivity in the evening or at night that relieve with movement. With regard to drug-induced
PLMS, which are repetitive movements typically in the lower limbs, several kinds of 
antidepressants (e.g. tricyclics [149]) can be identified as culprits. In addition to 
antidepressants (e.g. SSRIs [150]), monoaminooxidase B inhibitors (e.g. selegiline [151]) and
beta-adrenoreceptor antagonists (e.g. bisoprolol [152]) can serve as offending agents in the 
background of drug-induced RBD/RSWA, which is characterized by a complex pathological
motor behavior during REM sleep. The first line intervention in cases of RLS, PLMS and 
RBD/RSWA should be the cessation of the offending agents [140].
Myokymia, which is an involuntary trembling of few muscles or some bundles within a 
muscle without changing the position of joints, can be evoked by calcium channel blockers 
(e.g. flunarizine [153]), antimicrobials (e.g. cefepime [154]), antirheumatics (e.g. gold [155])
and fibrates (e.g. clofibrate [156]) as well.
Drug-induced myorhythmia (i.e. Holmes tremor) is an extremely rare condition, it has been
reported only as a side-effect of interferon alpha-2a therapy [157].
3. Conclusions
DIMDs represent a specific aspect of patient care. On the one hand, the significance of 
DIMDs is that they generally represent a potentially treatable condition among a group of 
reminiscent disorders where merely symptomatic therapy is available if any. Therefore, when
we observe a patient with a relatively recent-onset movement disorders, the possibility of 
DIMDs should always be considered among other secondary and treatable conditions. 
Furthermore, on the other hand, we should be very cautious with the application of 
medications with the potential of inducing serious side effects that include movement 
disorders. From this aspect, these kinds of medications are ought to be applied for as short 
duration and in as low dose as the appropriate management and the condition of the patients 
allows.
4. Expert opinion
In recent years, significant improvements have been achieved with regard to the side-effect 
profile of key groups of pharmaceutical agents (e.g. antipsychotics, antidepressants and 
gastrointestinal agents). Although the development of new generations of these kinds of drugs
may help in the prevention or reduction of the frequency of DIMDs, most of them cannot 
provide complete safety. Furthermore, there are other groups of medications (e.g. 
antimicrobials, chemotherapeutics) where drug development mainly aims at the preservation 
or improvement of effectiveness without worsening the side-effect profile. Therefore we often
face the challenge to achieve the required therapeutic effect with only minimal side effect. 
However, the appropriate dosing should be determined ubiquitously on individual basis, 
because we still lack the knowledge to determine why some patients are relatively resistant to 
therapeutic doses of drugs with the potential of evoking DIMDs while others are not. 
Accordingly, in addition to drug development, a special attention should be paid to the
exploration of genetic and environmental factors influencing drug responsiveness, interactions
and side effect profile.
The next most important aspect of DIMDs is the fact that they are frequently overlooked by 
the clinical community. This issue holds special importance, because most of DIMDs are 
potentially reversible with the cessation of treatment, reduction of dose or substituting the 
offending agent with a substance having better side-effect profile. From this point of view, 
much more efforts should be made by movement disorder specialists and pharmacists for the
dissemination of knowledge essential for the establishment of the right diagnosis. 
Furthermore, the prescription of drugs with potentially serious side effects should be 
restricted to experts in the respective fields, because many drugs in relation to DIMDs are 
prescribed with inappropriate indication, dose and duration.
With regard to reducing the prevalence of DIMDs the following considerations should be kept
in mind in relation to the subsequent groups of pharmaceutical agents where the choice of
drug or dose have special implications: 1) neuroleptics: the preferred use of atypical agents in 
low therapeutic doses; 2) mood stabilizers: paying close attention to the narrow therapeutic 
range of lithium; 3) calcium channel blockers: the preferred use of new generation agents with
better side-effect profile; 4) gastrointestinal agents: the preferred use of new generation agents
(e.g. famotidine rather than cimetidine or ranitidine) with lower penetration through the
blood-brain barrier (e.g. domperidon rather than metoclopramide); 5) antiepileptics: paying 
close attention to the proper application of drugs keeping serum levels in therapeutic ranges;
6) antimicrobials: targeted antimicrobial therapy in the appropriate dose for only the 
necessary duration; 7) opioids: only when NSAIDs are not effective as pain killers; 8)
hypnotics: the preferred application of non-benzodiazepine hypnotics.
Most of DIMDs are related to the unspecific adverse action of the offending agents in the 
basal ganglia and in the cerebellum. Therefore future research should aim not only at the 
development of drugs with much higher selectivity and better side-effect profile, but also at
the better characterization of neurochemical profile of the affected functional systems.
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Figure caption
Figure 1. The schematic depiction of the neurochemical aspects of striatal architecture. (5-HT
– serotonin, 5-HT
x 
– serotonin receptor, α
2 
– alpha-2 adrenergic receptor, ACh –
acetylcholine, AMPA – alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, 
A
2A 
– adenosine 2a receptor, β
1 
– beta-1 adrenergic receptor, δ – delta opioid receptor, DA – 
dopamine, DRN – dorsal raphe nucleus, D
x 
– DA receptor, ENK – metenkephalin, FSI – fast- 




receptor, Glu – 
glutamate, GPe – globus pallidus pars externa, H – histamine, H
x 
– histamine receptor, κ – 
kappa opioid receptor, LC – locus coeruleus, LTN – laterodorsal tegmental nucleus, LTS – 
low-treshold spiking interneuron, µ – mu opioid receptor, M
x 
– muscarinic acetylcholine 
receptor, MSN – medium-sized spiny neuron, NA – noradrenaline, nACh – nicotinic 
acetylcholine receptor, NMDA: N-methyl-D-aspartate receptor, NO – nitrogen monoxide, 
NPY – neuropeptide Y, PPN – pedunculopontine nucleus, SNpc – substantia nigra pars 
compacta, SOM – somatostatin, SP – substance P; glutamate, the black plain figures represent
inhibition, while white plain figures excitation; the reduced size of plain figures or dashed 
arrows represent subdominant effect; the arrows represent synaptic connections, while
boutons without arrows dominantly volume transmission)
Figure 1
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Table 1. The list of pharmacological classes of drugs with the potency of inducing movement disorders.










Antidepressants + + + + + + +
Antiepileptics + + + + + +
Antipsychotics + + + +
Antimicrobials + + + + +
Antiemetics + + + + +
Antiarrhythmics + + + +
Mood stabilizers + +
Opioids + + +
Chemotherapeutics + + + +
Ca2+-channel blockers + + +
Antiparkinson + +
Psychostimulants + + +
Hormones +




Central muscle relaxants +


























AChE – Acetylcholinesterase, Ca2+ – Calcium, DA – Dopamine, DIA – Drug-induced ataxia, DIC – Drug-induced chorea, DID – Drug-induced
dystonia, DIM – Drug-induced myoclonus, DIP – Drug-induced parkinsonism, DIM – Drug-induced myoclonus, DIT – Drug-induced tremor, 
DITic – Drug-induced tic, H
2 
– Histamine-2 receptor, INFα2a – interferon alpha-2a, NMS – Neuroleptic malignant syndrome, NSAID – Non- 
steroid anti-inflammatory drug, PLMS – Periodic limb movements of sleep, RBD – Rapid eye movement (REM) behavior disorder, RLS –
Restless legs syndrome, RSWA – REM sleep without atonia, SS – Serotonine syndrome.
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